Genmab A/S Release: HuMax-CD38 Shows Unique Property In Preclinical Studies

COPENHAGEN, Denmark, June 8 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) announced today that HuMax-CD38 was shown to inhibit the enzymatic activity of the CD38 molecule in preclinical studies. HuMax-CD38 is the first antibody known to block the ecto-enzymatic activity of CD38. This special property may contribute to the effectiveness of HuMax-CD38 in killing both primary multiple myeloma and plasma cell leukemia cells.